Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06225921 | Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05927844 | XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma | unknown | Phase 1 | 20 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 3, 2023 | clinicaltrials |
| NCT03094884 | Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer | unknown | Phase 1 | 40 | Fox Chase Cancer CenterOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05777707 | Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma | unknown | Phase 1 / Phase 2 | 89 | Beijing Friendship HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT04460066 | A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05317325 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02970539 | Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 2 | Feb 16, 2022 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04229537 | Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC | unknown | Phase 1 | 60 | Sinocelltech Ltd.INDUSTRY | 0 | Jan 18, 2020 | clinicaltrials |
| NCT03817567 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03757754 | HPPH Photodynamic Therapy for Patients With Esophageal Cancer(HPPH) | unknown | Phase 1 | 30 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 29, 2018 | clinicaltrials |
| NCT03706326 | CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03213054 | A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer | unknown | Phase 1 | 12 | Oncolys BioPharma IncINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT02762474 | Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer | unknown | Phase 1 / Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02662348 | T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System | unknown | Phase 1 | 6 | Yi MiaoOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00425425 | Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer | unknown | Phase 1 / Phase 2 | 43 | Technical University of MunichOTHER | 1 | May 1, 2014 | clinicaltrials |
| NCT00903136 | Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus | unknown | Phase 1 / Phase 2 | 50 | US Department of Veterans AffairsFED | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | unknown | Phase 1 | 50 | University Hospital FreiburgOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT01993784 | Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 9 | Peking UniversityOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00566800 | Erlotinib in Treating Patients With Barrett Esophagus | unknown | Phase 1 | 25 | Kansas City Veteran Affairs Medical CenterFED | 1 | Sep 17, 2013 | clinicaltrials |
| NCT01930630 | ESI With EUS to Differentiate T3 and T4 ESCC(ESI) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | Aug 29, 2013 | clinicaltrials |
| NCT01843049 | Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer | unknown | Phase 1 / Phase 2 | 40 | Fudan UniversityOTHER | 1 | Apr 30, 2013 | clinicaltrials |
| NCT00821912 | TaxXel: Taxotere and Xeloda in Esophageal Cancer(TaxXel) | unknown | Phase 1 / Phase 2 | 93 | Karolinska University HospitalOTHER | 2 | Feb 28, 2012 | clinicaltrials |
| NCT00632333 | Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer | unknown | Phase 1 | 9 | Teikyo UniversityOTHER | 1 | Jul 21, 2011 | clinicaltrials |
| NCT00669292 | PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer | unknown | Phase 1 / Phase 2 | 29 | Wakayama Medical UniversityOTHER | 1 | Sep 9, 2010 | clinicaltrials |
| NCT00915850 | Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 1 / Phase 2 | 32 | Wakayama Medical UniversityOTHER | 1 | Sep 9, 2010 | clinicaltrials |
| NCT01043016 | Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors | unknown | Phase 1 | 18 | Fujian Longhua Pharmaceutical Co. LtdOTHER | 1 | Jan 6, 2010 | clinicaltrials |
| NCT00008047 | Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus | unknown | Phase 1 / Phase 2 | — | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Feb 9, 2009 | clinicaltrials |
| NCT00682227 | Peptide Vaccination in Treating Patients With Esophageal Cancer | unknown | Phase 1 | 10 | University of YamanashiOTHER | 1 | May 29, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Oct 2, 2024source: clinicaltrials